Biota Holdings Limited Release: Inavir(R) Approved for Sale in Japan

Published: Sep 13, 2010

MELBOURNE, Australia--(BUSINESS WIRE)--Biota Holdings Limited (ASX:BTA) today announced that Daiichi Sankyo has received approval to manufacture and market Inavir® (pronounced in-a-veer) in Japan. Inavir® is Daiichi Sankyo’s brand of laninamivir octanoate and also previously known as CS-8958. The approved indication is for the treatment of influenza in adults and children.

Back to news